ArticleOpen forum infectious diseases2026
Incidence of Recurrent Respiratory Papillomatosis (RRP) in Denmark and Sweden During 2000-2023: Two Nationwide Cohort Studies in Children and Young Adults.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Recurrent respiratory papillomatosis (RRP), primarily caused by human papillomavirus (HPV) types 6 or 11, is a rare but high-morbidity condition. Nationwide estimates of the incidence of RRP are scarce, and we aimed to estimate the incidence of RRP among children and young adults in Denmark (2000-2023) and Sweden (2000-2021). Methods: Using the Danish Pathology Register and the Swedish Patient Register, we identified all individuals with a first-time occurrence of RRP (definition in Denmark: histologically confirmed, topography code T24 plus SNOMED codes for papillomas; Sweden: International Classification of Diseases-10 code D14.1A for papillomas). Incidence rates were calculated as number of RRP cases per 100 000 person-years (py), stratified by country, sex, and age groups at onset (0-14/juvenile 15-29/adult). Trends in incidence were evaluated in the period before and after introduction of HPV vaccination using Poisson regression to estimate the annual percentage change (APC) and 95% confidence intervals (CI). Results: We found juvenile-onset RRP incidences of 0.14 to 0.20/100 000 py as well as adult-onset RRP incidences at 0.19 to 0.40/100 000 py for women and 0.52 to 0.68/100 000 py for men in the postvaccine introduction period. Danish data showed a decreasing trend in RRP during the period following implementation of HPV vaccination, especially among young adults (women: APC = -11.5 [95% CI, -20.9 to -0.9]; men: APC = -11.0 [95% CI, -16.6 to -4.9]), whereas Swedish data did not show any clear decrease in RRP over time. Conclusions: The incidence of RRP is decreasing in Denmark but not in Sweden. This may be the result of more intense HPV vaccination programs, in particular early catchup vaccination of young adults, in Denmark as compared to Sweden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.